Many preclinical and clinical studies have been performed to determine RT response in different molecular subtypes of breast cancer, and sensitivity to radiation seems to be higher in hormone-positive tumors as compared to that of HER2-type or TNBC [6]. This evidence concerns the gene ERBB2 and breast cancer.